Characteristics of Sotos syndrome by Boer, L. de
  
 
 
 
CHAPTER 7 
 
 
GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 114
 115 
'LVFXVVLRQ
In this chapter, the following questions, formulated in the introduction, will be 
answered and the answers will be discussed.  
What is the cause of Sotos syndrome? Is the IGF system involved? Furthermore what 
are the clinical and psychological characteristics and are these correlated with the 
genotype?  
 
$HWLRORJ\RI6RWRVV\QGURPH
The genetic cause of Sotos syndrome was elucidated in 2002 (14). A child with Sotos 
syndrome and the following translocation: 46, XX,t(5;8)(q35;q24.1) was reported (11). 
The gene disrupted by the 5q35 breakpoint was identified as NSD1. Subsequently, 42 
Japanese individuals with Sotos syndrome were screened for deletions and mutations 
of this gene and 24 gene alterations were found (57% of the cases). The detected gene 
alterations consisted of 83% hemizygous deletions and 17% heterozygous mutations of 
the NSD1 gene. Haploinsufficiency of NSD1 was indicated as the major cause of 
Sotos syndrome. Since this report several European studies were published in which a 
percentage of 67-90% of NSD1 gene alterations was found among patients with typical 
Sotos syndrome (5, 20, 23). In the majority of these cases, mutations were detected 
instead of gene deletions. 
 
In our own study only one patient with atypical Sotos showed a 46, 
XY,t(5,15)(q35;22) translocation (chapter 3). FISH analysis did not show a deletion of 
the NSD1 gene. Unfortunately he did not give consent for further research and 
mutation analysis was not performed. 
After the  publication of  Kurotaki et al  (14), we  investigated  NSD1 gene alteration 
in  a  group of 59 patients clinically suspected of Sotos syndrome (chapter 2). We 
found 19 different  heterozygous  mutations  in 23  patients  (including  two families) 
in 1 copy  of  the NSD1 gene and 4 deletions of 1 copy. The highest percentage of 
gene alterations was detected in a selected group of patients with typical Sotos 
syndrome (81%). This was in agreement with other studies (5, 20), although 
categorisation of the patients was not exactly identical in the different studies. 
It is not yet clear what the cause is of the typical phenotype in cases without a detected 
NSD1 gene alteration (NSD1+/+ 19% in our study), and what the aetiology is in the 
patients with less typical features without NSD1 gene alteration. With the techniques 
used, not all NSD1 gene mutations will be detected (i.e. splicing variants due to 
deletions or mutations in introns or mutations in the promoter region of NSD1). Future 
research should focus on other techniques (e.g. MLPA, multiple ligation dependent 
probe amplification) to detect NSD1 gene alterations. Probably, besides NSD1, many 
other genes are involved in overgrowth and clinical characteristics of Sotos syndrome. 
Other related genes will have to be discovered. It has recently been shown that 3 
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copies of an IGF1-R causes a Sotos-like phenotype (see below), which makes the 
IGF1-receptor gene a candidate gene for further analysis. 
In Japanese patients gene deletions accounted for the majority of the phenotypes 
whereas in European patients intragenic mutations were the major cause. Several 
explanations for this have been proposed. First it was expected that with screening 
more patients, more deletions would be been found (5). As more reports indicated that 
intragenic mutations accounted for most of the cases in European countries, this view 
was not sustainable. A specific Japanese genomic structure or sample selection bias is 
a possibility (15). Up till now no specific hotspots for mutations have been identified. 
Nonsense, frame shift and splicing mutations are distrubuted over the whole gene, 
while missense mutations were preferentially located between exon 13 and 23. 
 
 
The function of NSD1 is not yet fully understood. The protein has two nuclear receptor 
(NR) interaction domains and can act both as a NR corepressor or coactivator. It can 
interact in presence or absence of ligands with the retinoic acid receptor, thyroid 
hormone receptor and estrogen receptor (10). These nuclear receptors play an 
important role in growth regulation. The thyroid hormone receptor and retinoic acid 
receptor also seem important in intra-uterine growth regulation. It has been postulated 
that NSD1 acts as a corepressor of growth promoting genes leading to overgrowth in 
Sotos syndrome (14). From the results shown in this thesis it can be postulated that 
NSD1 either directly or indirectly influences the IGF system (chapter 4). Clinically it 
at least leads to overgrowth, increased arm span for height, increased hand length and 
typical facial characteristics (chapter 2 and 5). 


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Reports about IGF-I and IGF-IR gene alterations in animals and man have contributed 
to our hypothesis that overactivation of IGF plays a role in overgrowth in patients with 
Sotos syndrome. In transgenic mice overexpressing IGF-I, prenatal overgrowth was 
seen and small birth sizes were found in knockout mice for IGF-I, IGF-II and IGF-IR 
(12). In humans, a patient with total deficiency of IGF-I, caused by a homozygous 
partial deletion of the IGF-I gene, was described (24) with ‘opposite’ features of Sotos 
syndrome. This patient showed prenatal growth retardation, microcephaly, a low 
hairline and micrognathia. A recent report (18) described a patient with prenatal 
overgrowth and Sotos-like features with 3 copies of the IGF-IR gene and a patient with 
prenatal and postnatal growth retardation and 1 copy of the IGF-IR.  
 
To study a possible relationship between the IGF system and Sotos syndrome we 
investigated plasma levels of IGFs, IGFBPs, ALS and IGFBP-3 protease activity 
(chapter 3, 4). In addition we used skin fibroblasts to study local IGF/IGFBP system 
activity (chapter 4). We found modest endocrine as well as paracrine differences in the 
IGF system between NSD1+/- patients and controls or NSD1+/+ patients pointing to a 
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relationship between NSD1+/- and the IGF system. However the changes did not point 
to the hypothesized overactivation of IGF-I. In comparison with reference values 
NSD1+/- patients showed decreased levels of the IGFs in plasma, decreased levels of 
IGFBP-3 and IGFBP-4 and increased levels of IGFBP-2 and 6, two inhibitors of IGF 
action. In skin fibroblasts a lower basal proliferation activity was detected with a lower 
response to IGFs in comparison with controls. 
 
 
With these IGF characteristics one would expect patients with short stature, rather than 
tall stature. It could be speculated that high IGFs and/or low inhibiting IGFBPs 
circulate only in the period of the highest growth velocity. The highest growth velocity 
in the patients with Sotos syndrome is prenatally and in the first year after birth, but 
plasma values in our study have only been measured in patients 2.1 years and older. 
Another explanation is that steady-state IGF plasma levels do not reflect the 
bioavailability at the target tissue level. In part, bioavailability of IGFs depends on 
IGFBPs and its proteases (12) and the actual tissue of interest concerning growth is the 
growth plate. By our studies (chapter 4) it is shown that NSD1 gene alteration is 
associated with changes in the IGF system. It is possible that these changes reflect 
local changes at the growth plate favouring overgrowth. On the other hand these 
changes could also be part of a negative feed back loop inhibiting the overgrowth 
induced by NSD1 gene alterations. As discussed in chapter 4 this is not sustained by 
the finding of a lower proliferation rate measured by [methyl-3H] thymidine in the skin 
fibroblasts. 
 
 
Mean IGFBP-6 plasma levels showed the highest difference compared to reference 
values (+1.5 SDS) in NSD1+/- patients. It is known that this IGFBP binds to IGF-II 
with a higher affinity than to IGF-I and acts as an IGF inhibitor (19). Together with 
IGFBP-2 it is the main IGFBP in cerebrospinal fluid, produced in the central nervous 
system. It could be speculated that these findings relate to cerebral overgrowth or 
developmental delay. However no difference was found in developmental delay 
between NSD1+/+ and NSD1+/- and the difference in head circumference did not reach 
significance. 
It is possible that NSD1 expression influences IGFBP-6 expression through interaction 
with retinoic acid and its receptor. The IGFBP-6 promoter contains retinoic acid 
response elements and an animal study showed that IGFBP-6 transcription in skeletal 
cells was stimulated by retinoic acid (4, 7).  
 

&OLQLFDOFKDUDFWHULVWLFVLQ6RWRVV\QGURPH
Overgrowth, one of the main characteristics of Sotos syndrome, was more extreme in 
NSD1+/- patients compared to NSD1+/+ patients as calculated by repeated measures 
analysis (chapter 2). No study has compared height data between NSD1+/- and 
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NSD1+/+, but a French study (20) reported that overgrowth was not a consistent finding 
in NSD1+/- patients, whereas others did find overgrowth in the majority of the NSD1+/- 
patients (16, 23). 
 
 
Firstly birth size parameters are discussed. For birth length of NSD1+/- patients, we 
found a mean value of 1.4 SDS in 13 patients (chapter 5) and in a larger group of 23 
patients 1.9 SDS (chapter 2), which is significantly elevated compared to the reference, 
but not in comparison with NSD1+/+ patients (0.8 SDS in 15 patients and 1.0 SDS in 25 
patients). This was also found for head circumference, NSD1+/- 1.2 SDS in 13 patients 
and 1.5 SDS in 17 versus 1.0 SDS (n=15) and 1.2 SDS (n=24) in NSD1+/+ patients. 
Mean birth weight in NSD1+/- patients was not significantly different from the 
reference population nor from the NSD1+/+ patients. In one other study (16) birth size 
parameters were reported. In this study no significant difference was reported between 
patients with mutations and with deletions. No information was provided about the 
difference between NSD1+/- and NSD1+/+. 
Correction for target height, not described in other studies has been shown useful 
(chapter 5) to discriminate between NSD1+/+ and NSD1+/-. The difference between the 
two subgroups was larger with this correction (NSD1+/- 1.8 SDS vs. NSD1+/+ 0.9 SDS, 
p=0.06), than without this correction (1.9 SDS vs. 1.4 SDS, p=0.40). This indicated 
that familial or genetic tall stature contributed to overgrowth in the NSD1+/+ group. 
 
 
One of the objectives of our study was to evaluate final height in patients with Sotos 
syndrome. In the literature final height of 11 patients with the clinical diagnosis of 
Sotos syndrome was reported in the normal range (1). In our study, final height was 
reached in nine patients with NSD1 gene alterations (chapter 2). The mean value was 
0.9 SDS, which did not point to an extremely tall final height in agreement with the 
literature. There is no indication that many patients need treatment, because treatment 
is usually considered if height estimation is above 2 to 2.5 SDS. 
 
 
No significant differences were found for mean sitting height/ height ratio between 
both subgroups. In both the ratio was decreased (chapter 5). Other auxology measures 
showed higher arm span after correction for height and hand length in the NSD1+/- 
group. Foot length showed a trend towards higher measures in NSD1+/- patients (2.1 
SDS vs. 0.7 SDS. p=0.06). 
Repeated measures analysis showed that head circumference SDS in NSD1+/- patients 
tended to be higher than in NSD1+/+ patients, but this did not reach significance 
(p=0.06) (chapter 3). Mean head circumferences in adults were 2.8 (NSD1+/-, n=7) and 
2.6 (NSD1+/+, n=7). 
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Bone age SDS as calculated by the Greulich & Pyle method was advanced in the 
NSD1+/- group (mean of all available X-rays: 2.7 SDS, chapter 2), but was not 
discriminating between the two subgroups.  
Of six regularly described facial characteristics in Sotos syndrome, four showed a very 
high discriminating value: frontal bossing, high hairline, downslant palpebrals and 
pointed chin, whereas two others dolichocephaly and high arched palate were not 
significantly different between the two subgroups (chapter 2). Facial gestalt correlated 
well with the genotype, which was in agreement with other studies (5, 20). 
 
 
In 1994 Cole et al suggested four major criteria for Sotos syndrome: facial gestalt, 
growth pattern, bone age and developmental delay (3), which have been used as a 
guidance in many studies. In order to objectivate the importance of the different 
criteria, a clinical score was introduced (chapter 3). This score reflected the decision 
making of a panel of clinical geneticists to categorise patients as typical, dubious or 
atypical Sotos syndrome. After discovery of the NSD1 gene we evaluated this score 
for its predictive value for NSD1 gene alterations. The total score had a high predictive 
value (p< 0.001). The subscores for developmental delay and advanced bone age were 
consistent findings in the preselected group, but not discriminating between patients 
with and without NSD1 gene alteration. The subscore for growth tended to be higher, 
but the difference did not reach significance (p=0.07). The subscores head 
circumference and facial characteristics discriminated between the two subgroups, 
with the highest predictability for the last one (chapter 2).  
 
 
In order to describe the variables with the highest predictive value an adjusted score 
was calculated by logistic regression analysis. This resulted in the following score: 
total score= 2x (frontal bossing) + 1x (downslant palpebrals) + 1x (pointed chin) + 
0.5x (growth score). Frontal bossing was found to be the most important characteristic. 
The marks in the growth score can be 0, 0.5 or 1. The total score ranges from 0 till 5. 
The calculated optimal cut-off limit was > 3.5, with this value the positive likelihood 
ratio was 3.16 (chapter 3). Although this score will need to be tested in new groups of 
patients, it can be used to assist selecting patients for mutation or deletion analysis.In 
this study the new score was used to describe the most important discriminating 
parameters between NSD1 mutations and deletions and a normal NSD1 gene in a 
preselected group of patients clinically suspected of Sotos syndrome.  
From our familial cases we have learned that there is a milder phenotype without 
developmental delay or decreased cognitive function. These patients came under 
medical attention because their children showed Sotos syndrome. It also seems that 
with ageing the phenotype becomes milder. Consequences for these patients 
themselves may be small, but it could have consequences for their children, who could 
show a more pronounced phenotype. 
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In chapter 2 the incidence of clinical problems is reported. Incidence of feeding 
problems in the first year was higher in the NSD1+/- group (86%) compared to the 
NSD1+/+ group (35%). Other studies have not compared the two subgroups, but in one 
study a lower incidence was reported of 6 out of 22 NSD1+/- patients having had 
feeding difficulties. The estimation of incidence of cardiac anomalies in Sotos 
syndrome has been high (8%), especially in Japanese reports (35%-50%), in 
comparison with the incidence in the general population (0.6-1%) (13, 17, 22). 
Comparison between patients with a deletion and a mutation in the NSD1 gene pointed 
in one study to a higher incidence in the group with deletions (16) and in one study 
(20) no difference was detected. A comparison between NSD1+/- and NSD1+/+ was not 
yet made. Although a small number of patients were known with cardiac anomalies in 
our study (n=5), the incidence was higher in NSD1+/- than in NSD1+/+ patients (21% 
vs. 0%).  
 
Problems as neonatal jaundice, hypotonia, strabismus, febrile convulsions, scoliosis, 
pes planus and otitis occurred in the NSD1+/- patients, but the incidence did not differ 
from NSD1+/+ patients. No cases of epilepsy were known in the NSD1+/- group. Brain 
anomalies on CT or MRI were found in both groups (NSD1+/- 63%, NSD1+/+ 47%). 
We did not have complete clinical information of all patients. 
 
Casuistic description of family members of Sotos patients showing a higher incidence 
of abortions have led some authors to conclude that infertility is associated with Sotos 
syndrome (2, 9, 21). In our study (chapter 2), a mother with characteristics of Sotos 
syndrome and a NSD1 mutation, gave birth to two children with Sotos syndrome, after 
IVF. This indeed points to a possible relationship between Sotos syndrome and 
infertility. The reason for this is unknown. Experimental data in NSD1 knock out mice 
suggest that homozygous deletion of NSD1 is embryonic lethal with time point of 
death early in gestation  
 
Sotos syndrome has been associated with a higher incidence of malignancies (8). As 
discussed before in the introduction the numbers could be biased. Diverse tumours of 
various tissue origin have been described. In our study of 59 patients with Sotos 
syndrome, no patients were known to have a malignancy.  
 
 
3V\FKRORJLFDOFKDUDFWHULVWLFV
The incidence of developmental delay in terms of delayed motor or speech milestones  
or mental retardation (IQ score < 70) (chapter 2 and 6) was not significantly different 
in both subgroups. This is in agreement with a French study (20). In that and another 
study (16) a tendency towards more severe mental retardation in patients with 
deletions was described. We did not find this in our study, but one has to realise that 
the number of patients with a deletion in our study was very small (n=4, chapter 2). 
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Cognitive functioning in 7 NSD1+/- patients was assessed by IQ tests in our study. A 
mean IQ was 70 (chapter 6). Results for 4 more patients were collected in a larger 
study (chapter 2) and for these 11 patients together mean IQ was 75 (range 47-107). In 
this thesis for the first time IQ data have been related to NSD1 gene alterations. No 
significant differences were found in comparison with NSD1+/+ patients (mean IQ 78, 
range 48-105, n=17). Both groups showed a wide range of IQ scores.  
 
As described in chapter 6 we found in NSD1+/- patients a wide range of behaviour 
problems, problems in adaptive behaviour and decreased health related quality of life 
as reported by the parents on  several  scales. The scales were related to motor 
functioning, communication, social functioning, cognitive functioning and autonomy. 
Most of these problems were also reported in NSD1+/+ patients. Differences between 
the two subgroups pointed into the same direction of less severe problems in the 
NSD1+/- group. Less NSD1+/- patients scored in the clinical range for behaviour 
problems as assessed with the CBCL, less scored in the clinical range for ADHD and 
their temperament was classified as easier. Significantly more patients of the NSD1+/+ 
group lived in an institution. No other studies have reported on psychological 
characteristics in relation to NSD1 gene alterations. Although we have to be careful 
with drawing conclusions from these small groups, the tendency towards less severe 
problems in NSD1+/- patients is noteworthy. It is of interest that ADHD has been 
related to clinical Sotos syndrome in earlier reports(6), but this could not be confirmed 
in our study for NSD1+/- patients. 
 
&RQFOXGLQJUHPDUNVDQGIXWXUHUHVHDUFK
For the patients clinically suspected of Sotos syndrome it can be concluded from this 
thesis that NSD1+/- patients compared to NSD1+/+ patients show more typical facial 
characteristics (frontal bossing, high hairline, downslant palpebrals, pointed chin), 
more extreme overgrowth, a higher arm span for height, a more increased hand length 
and a higher incidence of feeding problems and cardiac anomalies. In vitro they show 
lower circulating levels of IGFs, IGFBP-3 and –4, higher circulating levels of IGFBP-
2 and –6, a decreased response to IGFs and higher IGFBP-3 mRNA expression in skin 
fibroblasts. Psychologically they tend to have less severe problems in behaviour, 
ADHD and temperament. 
 
Future research could focus on the patients with clinical characteristics of Sotos 
syndrome, but without detected mutations or deletions. It is possible that the NSD1 
gene is involved, but that with the techniques used, the aberrations were not detected. 
With other techniques (e.g. MLPA) this could be explored. Another possibility is that 
another gene alteration causes their phenotype. The fact that this group can be 
clinically and endocrine/paracrine discriminated from the NSD1+/- group favours this 
possibility. Duplication of the IGF-IR gene leading to three copies has been described 
in one patient with Sotos like clinical characteristics. We have recently discovered this 
in a NSD1+/+ patient with clinical characteristics of Sotos syndrome. 
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Genes related to NSD1 could be of interest for further exploration of NSD1 function. 
In chapter 4 it is suggested that IGFBP-6, which is elevated in plasma of NSD1+/- 
patients, relates to NSD1. Studying IGFBP-6 expression in different tissues (e.g. 
growth plate) in humans could indicate if a relation to overgrowth is likely. With 
techniques as micro-array, differences in gene expression between the two subgroups 
could lead to other genes involved. Possibly genes could be identified explaining the 
mechanism by which NSD1 gene alteration induces overgrowth. Of special interest 
would be IGF and IGFBP gene expression. 
 
One could question if there is reason for follow up or screening with regard to the 
clinical problems mentioned. Paediatric care will be needed in cases of neonatal 
jaundice, feeding problems and hypotonia. This could also include referral to 
physiotherapists, speech therapists or psychologists. Paediatric follow up is probably 
also useful for growth monitoring and overgrowth related problems as scoliosis and 
pes planus. A cardiac ultrasound after the detection of a NSD1 gene alteration should 
be considered. The reported malignancies in the literature are various in kind and 
methods to detect them vary. Therefore doctors should be aware of the possible 
elevated risk, but screening does not seem indicated. 
 
In conclusion, with the identification of the NSD1 gene, an important cause of Sotos 
syn drome and overgrowth has become accessible to research. The results of the IGF 
and IGFBP characteristics in patients with Sotos syndrome show that more research 
will be needed to elucidate the chain of signals in which haploinsufficiency of NSD1 
causes overgrowth. 
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